Drugs / Pimasertib
Pimasertib
also known as
MSC1936369B · AS 703026 · EMD 1036239 · EMD 1036950 · G-02443714 · Msc-1936369 · MSC-1936369A · Msc1936369a; as703026; emd 1036239 · +1 more
Small molecule targets MAP2K1, MAP2K2 via inhibition
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT07121829 | May 2022 → Dec 2024 | colorectal cancer, malignant pancreatic neoplasm, melanoma, non-small cell lung carcinoma +1 | Day One Biopharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01992874 | Nov 2013 → May 2014 | neoplasm | EMD Serono | Completed | No outcome recorded |
| Phase 1 | NCT01985191 | Nov 2013 → Feb 2016 | cancer | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01713036 | Nov 2012 → Jul 2014 | — | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1 | NCT01668017 | Sep 2012 → May 2015 | hepatocellular carcinoma | Merck KGaA, Darmstadt, Germany | Terminated | No outcome recorded |
| Phase 1 | NCT01378377 | May 2011 → Feb 2012 | neoplasm | EMD Serono | Terminated | No outcome recorded |
| Phase 1 | NCT01357330 | May 2011 → Jun 2012 | cancer | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01390818 | May 2011 → Apr 2015 | breast cancer, colorectal cancer, melanoma, metastatic neoplasm +1 | EMD Serono | Completed | No outcome recorded |
| Phase 1 | NCT00982865 | Dec 2007 → Mar 2013 | cancer | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04789668 | Jan 2021 → Dec 2023 | cutaneous melanoma, female breast carcinoma, hematopoietic and lymphoid cell neoplasm, hormone receptor-positive breast cancer +4 | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01085331 | Mar 2010 → Apr 2012 | colorectal cancer | EMD Serono | Terminated | No outcome recorded |
| Phase 1/2 | NCT01016483 | Nov 2009 → Dec 2013 | pancreatic adenocarcinoma | EMD Serono | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT01936363 | Sep 2013 → May 2015 | ovarian cancer | EMD Serono | Completed | No outcome recorded |
| Phase 2 | NCT01693068 | Dec 2012 → Jul 2015 | cutaneous melanoma | EMD Serono | Completed | Met primary |
| Phase 2 | NCT00957580 | Sep 2009 → Dec 2012 | acute myeloid leukemia | EMD Serono | Terminated | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pimasertib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00957580 ↗ |
| Known as | AS 703026 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107832 ↗ |
| Known as | EMD 1036239 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107832 ↗ |
| Known as | EMD 1036950 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107832 ↗ |
| Known as | G-02443714 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107832 ↗ |
| Known as | Msc-1936369 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107832 ↗ |
| Known as | MSC-1936369A | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107832 ↗ |
| Known as | Msc1936369a; as703026; emd 1036239 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107832 ↗ |
| Known as | MSC1936369B | “Pimasertib (AS703026 or MSC1936369B) is a selective inhibitor of MEK1/2, the mitogen-activated protein kinase (MAPK) signaling pathway, which is often dysregulated in cancer cells.” PMID 27934635 ↗ Dec 2016 |
| Known as | PIMASERTIB HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107832 ↗ |
| Action | Inhibit | “Dual specificity mitogen-activated protein kinase kinase 2 inhibitor” CHEMBL2107832 ↗2“Dual specificity mitogen-activated protein kinase kinase 1 inhibitor” CHEMBL2107832 ↗ “The selective MEK1/2 inhibitor pimasertib” PMID 29756206 ↗ Aug 2018 |
| Modality | Small molecule | — CHEMBL2107832 ↗ |
| Route | Oral | “Pimasertib will be administered orally at a dose of 8 mg twice daily (BID) on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle.” NCT00957580 ↗ |
| Target | MAP2K1 | “Dual specificity mitogen-activated protein kinase kinase 1 inhibitor” CHEMBL2107832 ↗ |
| Target | MAP2K2 | “Dual specificity mitogen-activated protein kinase kinase 2 inhibitor” CHEMBL2107832 ↗ |